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This ﬁnding will help to develop diagnostic tools that can be used
to predict treatment response before interferon-based ther-
apy. It also provides insights into the molecular mechanism of
interferon resistance in HCV infected patients.
PP-142 The predictive value of viral response during
treatment to sustained viral response obtaining
in chronic hepatitis C personalized treatment
programs
Ming-hui Li *, Yao Xie, Li-jun Chen, Guo-hua Qiu, Yao Lu,
Dao-zhen Xu. Deparment of Liver Diseases, Ditan Hospital,
Beijing, PR China
The antiviral effects of interferon in chronic hepatitis C is inﬂu-
enced by many factors, among which the personalized interferon
and RBV dose, treatment course were the most important. The
viral response during treatment was the composite expression of
factors associated with treatment effects, and the very impor-
tant predictive for sustained obtaining.
In this paper, the enrolled patients with chronic hepatitis C, were
given the intensive treatment doses of interferon and ribavin
according to their basic clinical condition. in the treatment of
0, 4, 12, 24 weeks, the end of threatment and 24 weeks after
treatment stop, the serum HCV RNA were ditermined, and ac-
cording the viral response on-treatment the individuation cours
was given, and the value of viral responses, including rapid viral
response, (RVR), deﬁneted serum HCV RNA undetectable at 4
week, and complete early viral response (cEVR), serum virus
undetectable at 4 week, on-treatment was anylised predictive
for SVR obtained. Given the personalized therapeutic program,
84.2% of patients obtained RVR, among which 90.7% obtained
SVR. The RVR was not associated with HCV genotypes (χ2=6.00,
p=0.112), but signiﬁcantly with serum HCV RNA load baseline
(t=2.15, p=0.034), which in RVR was lg 5.883±1.246 copies/ml,
and lg 6.502±0.693 copies/ml in non-RVR. The RVR rate (87.8%)
of vaive patients interferonα-2a was higher than that of re-
treatment patients (65.0%) signiﬁcantly in pegylated interferon
treatment group (χ2=4.651, p=0.031). 92.4% (122/132) of pa-
tients obtained cEVR, those in pegylated interferon α-2a 180mg,
135mg and standard interferon group were 90.5%, 95.0% and
90.4%, and the difference among the three groups was not signif-
icant difference (χ2 = 0.981, p = 0.640). The SVR rate of patients
with cEVR was SVR was 90.8% (108/119), which was signiﬁcantly
higher than that, 55.56% (5/9), of patients with no cEVR rate
(Fisher’s exact test, p = 0.007). The cEVR rate between naïve and
retreatment patients was not difference (χ2=1.993, p=0.158),
which were 94.7% (90/95) and 85% (17/20) respectively, and the
difference of cEVR rate between genotpye 1 and non 1 group was
not signiﬁcance aslo (χ2=6.000, p=0.112), 91.22% (52/57) and
96.29% (26/27) respectively. This study showed that, RVR and
cEVR were signiﬁcantly related to SVR, and personality therapy
can improve the obtaining probability of RVR, cEVR and the SVR.
According to the clinical characteristics of patients, given inten-
sive doses of interferon and RBV, adjusted drug dose timely, and
extended treatment of HCV RNA-negative course based on pa-
tient response were important in chronic hepatitis C personalized
treatment.
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PP-143 APOBEC3G/B/F mRNA levels in PBMC of
HIV-infected patients and there correlation with
CD4+ T cell counts
Zhenyan Wang*,1,2, Hongzhou Lu2. 1Shanghai Public Health
Clinical Center; 2Fudan University
Background: Apolipoprotein B mRNA-editing enzyme, catalytic
polypeptide-like 3G/B/F(hA3G/B/F) showed anti-HIV activity in
extro, though there correlation with HIV disease progression is
not clear. Our aim is to quantitative investigate hA3G/B/F mRNA
levels in HIV-infected patients, then analyze there correlation
with CD4 counts.
Methods: Peripheral blood samples were collected from 21 HIV-
infected subjects not taking antiretroviral therapy (ART) and
21 HIV-infected subjects receiving ART, and 10 HIV-uninfected
controls.hA3G/B/F mRNA levels in PBMC were determined by
real-time ﬂuorescent quantitative PCR. Flow cytometry was used
to detect CD4 counts.
Results: There was no correlation between hA3G/B/F mRNA lev-
els and CD4 counts in either ART+ or ART- HIV-infected subjects.
hA3G mRNA level in HIV-infected subjects was lower than that
in HIV-uninfected controls (P<0.05), but no statistical difference
between ART+ and ART- groups (P>0.05). However, signiﬁcant
difference were found in hA3B/F mRNA levels between the three
groups (P<0.05): ART- HIV-infected subjects < ART+ HIV-infected
subjects < HIV-uninfected controls. hA3G/B/F mRNA levels were
positively correlated with one another in ART+ HIV-infected sub-
jects and HIV-uninfected controls, while not in ART- HIV-infected
subjects.
Conclusion: hA3G/B/F gene expression levels do not directly
correlate with HIV-1 disease progression. Host hA3G/B/F expres-
sion levels tend to decrease after HIV-1 infection, and ART may
elevate hA3B/F mRNA levels, but not for hA3G. The function of
hA3 family proteins in anti-HIV infection needs further study.
PP-144 Substitution treatment implementations in
Ukraine – impact on HIV prevalence
Dmitry Metlitsky*. All-Ukrainian Network of PLWHAs
Substitution treatment is recognized as effective part of biomed-
ical preventions and one of the main tools of HIV/AIDS epidemic
control among IDU’s. ST admitted as essential choice for IDU if
ones fail rehabilitation programs.
Although Ukraine has the highest HIV-prevalence in Eastern-
Europe regions (large portion of vulnerable populations consists
of IDU’s), ST implementation was under the major focus of donors
(Global Fund, Sunrise, Clinton Foundation).
By the reason ST was quit new activity for Ukraine vertical model
of implementation – from center to regions were chosen. It
meant that advocacy for needed decrees from Ministry of Health,
drugs regulation authorities was made on the national level.
Then a number of regional sites were opened.
In result regional medical authorities asked for help in meeting
of requirement in ST sites, they started to participate in project
competitions for sites ﬁnancing, they realized advantages of new
model of work with IDU’s.
As conclusion it should be mentioned that central advocacy work
saved time and made regional implementation of program much
easier. As the second phase – regions begun plan their activities
accordingly needs of the regions. Governmental authorities were
satisﬁed with decreasing of HIV transmission among IDU, more
social reliability of patients and lower mortality rate among
them.
Statistic data is available.
PP-145 P53 and mitochondrial toxicity induced by AZT
Dexi Chen*, Yu Sun, Yasong Wu, Hao Wu, Xinyue Chen. Beijing
You An Hospital Capital Medicla University
The mitochondrial toxicity of nucleoside reverse transcriptase
inhibitors (NRTIs) is due to the inhibition of mitochondrial DNA
(mtDNA) polymerase γ (Pol γ), resulting in a blockade of mtDNA
replication and subsequent disruption of cellular energetics1.
Previous study showed that p53 play a direct role through in-
teraction with DNA Pol γ or mitochondrial transcription factor
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A (mtTFA) and indirect role via up-regulation of the p53R2
expression2-4. Recently more than 6 kinds of P53 isoform have
been reported and they played the different role in DNA repair
pathways, cell-cycle checkpoints and cell apoptosis5. P53 and its
different p53 isoforms play what kind of role in mitochondrial
toxicity induced by NRTIs is unclear. In this study, we identiﬁed
the role of wild type p53 and its isoforms (N40P53 and N133P53)
in mitochondrial toxicity induced by AZT and oxidative stress.
In this study we treated the A549 p53+/+, H1299 N40 P53+/+,
H1299 N133P53+/+ and H1299 P53-/- cell lines with 5 to 200
μM AZT for 12 hours for studying cell death and the expression
of p53R2, p21 and bax via p53R2 (Bax, P21) pGL3-Luciferase
reporter gene assay, real-time PCR and Western Blotting; treated
cells with 30uμM AZT for 5 weeks, 10 weeks and 1μM H2O2
for 1 hour/week to study the mtDNA mutation, mtDNA deletion
and mitochondrial toxicity. The cells were treated with p53R2
interference RNA to study the p53R2 how regulated the DNA Pol
γ capability.
The result showed that A549 p53+/+ cell death is more sensi-
tive to high concentration of AZT. The increased cell death was
detected from 120 uM of AZT and more that 80% cell were into
apaotosis in 2000 μM AZT. But other three cell lines have strong
tolerance to AZT toxicity. They are only less than 10% cell death
in 2000 μM AZT. The results from report gene assay and real-time
PCR assay suggested that wild type p53, N40 P53, N133P53 played
different role in p53R2, P21 and Bax promoters. All of wild type
and isoform P53 up-regulated the p53R2 expression, but isoform
P53 played a domain negative regulation in Bax expression. The
p21 expression was co-stimulated by wilde-type P53 and N40,
N133P53. D-loop of mtDNA mutation and mtDNA quatitiy assay
showed that A549 p53+/+ cell has lower mtDNA mutation rate
and almost no mtDNA loss following 5 weeks AZT stress. N40
P53,N133P53 cells have lower mtDNA mutation too, but mtDNA
loss is signiﬁcant higher than that in A549 P53 +/+ cells. H1299
P53 null cells has higher mtDNA mutation rate and mtDNA loss
than that in wild-type P53 and N40 P53, N133P53 isoform cells.
Conclusion: Both wild type and N40 P53,N133P53 isoform p53
play protect role in AZT induced mitochondrial toxicity. The
P53R2 would be involved in the centrol molecular pathway of p53
reduced mtDNA mutation and mtDNA loss induced by AZT
PP-146 Incidence and characterization of acute HIV-1
infection among high-risk self-identiﬁed men who
have sex with men in Beijing, China
Xiaojie Huang*, Haiying Li, Zhiying Liu, Caiping Guo,
Yanqing Gao, Zaicun Li, Yan Fu, Tong Zhang, Dexi Chen,
Xiaoning Xu, Hao Wu. Beijing YouAn Hospital, Capital Medical
University
Objective: To investigate the HIV incidence and the baseline
demographic data, clinical characteristics of acute HIV infec-
tions among self-identiﬁed men who have sex with men (MSM)
population in Beijing.
Methods: From May 2007 to February 2009, a hospital-based
cohort of HIV-uninfected MSM was established for a natural his-
tory study of HIV-1 infection. The cohort was followed every
two months to determine HIV incidence by pooling nucleic acid
testing (NAT) of third-generation enzyme immunoassay (EIA)-
negative samples.
Results: After screening 2861 individuals, a hospital-based co-
hort of 1529 uninfected high-risk MSM was established. During
1147.575 person-years of follow-up, 8424 samples were screened
for acute HIV infection by pooling nucleic acid testing (NAT)
of third-generation enzyme immunoassay (EIA)-negative sam-
ples (n =8221). HIV-prevalence at screening was 9.29% posing a
challenge in HIV-negative MSM. 63 infections occurred yielding
seroincidence rate of 5.49 per 100 person-years. 15 acute HIV-
infected subjects were identiﬁed by pooled NAT. Median HIV RNA
was 5.34 copies per milliliter (log10 viral load (VL) =220,000).
Conclusions: HIV prevalence in MSM population is signiﬁcantly
greater than that in the general population, which reﬂects the
current epidemic in Beijing and justiﬁes prevention programs
aimed at this group. This high-risk population may be suitable for
future studies on acute HIV infection, HIV treatment, vaccine,
and prevention of onward transmission strategies.
PP-147 Liver injury in HIV-1-infected patients receiving
non-nucleosides reverse transcriptase
inhibitors-based antiretroviral therapy
Zaicun Li *, Lili Dai, Yanqing Gao, Haiying Li, Xiaojie Huang,
Caiping Guo, Tong Zhang, Hao Wu. Clinical center for STDs and
AIDS at Beiijng Youan Hospital, Capital Medical University
Objectives: To study the features of liver injury in HIV-1-
infected patients receiving non-nucleosides reverse transcriptase
inhibitors-based antiretroviral therapy (ART).
Methods: 75 patients receiving non-nucleosides reverse tran-
scriptase inhibitors-based ART were retrospectively studied. The
patients were divided into 2 groups: liver injury group (n=45) and
non-liver injury group (n=30). The features of liver injury were
analysed. The prevelance of HBV and/or HCV, hepatotoxic drugs
use and NVP or EFV use were compared between two groups.
Results: 45 (60%) patients, 31 (68.9%) males and 14 (31.1%)
females, aged 12–52 years, averaged 39±9 years, experienced
at least one episode of liver injury. 40 (53.3%) co-infected with
HBV and/or HCV, 42 (56%) patients had concomitant use of an-
tituberculosis drugs, 46 (61.3%) and 29 (38.7%) received regimen
containing NVP or EFV, respectively. Grade 1 liver injury were
observed in 26 (34.7%) patients, grade 2 in 16 (21.3%), grade 3 in
2 (2.7%) and grade 4 in 1 (1.3%), respectikvely. 3 (4%) patients dis-
continued ART due to liver injury. There were 29 (64.4%) patients
coinfected with HBV and/or HCV, 32 (71.1%) received regimens
containing NVP, and 30 (66.7%) had concomitant use of antibu-
berculosis drugs in liver injury group, respectively, signiﬁcantly
higher than those in non-liver injury group [11 (36.7%), 14 (46.7%)
and 12 (40%), respectively. P=0.018, 0.033, 0.023, respectively].
Conclusions: Liver injury in HIV-1-infected patients receiving
non-nucleosides reverse transcriptase inhibitors-based antiretro-
viral therapy was mild to moderate, those who coinfeted with
HBV and/or HCV, had cocomitant use of antibuberculosis drugs
or cotrimoxazole and received a regimen containing NVP were
prone to liver injury.
PP-148 Simultaneous disseminated mycobacterium avium
complex (MAC) and pulmonary cryptococcosis in
an AIDS patient: presentation of immune
reconstitution inﬂammatory syndrome (IRIS)
requiring corticosteroid therapy
Azadeh Nasseh*, Baya Omidnia, Ladan Ahmadi. Department of
Medicine; Lenox Hill Hopsital; New York, NY, USA
Introduction: Immune reconstitution syndrome, caused by
restoration of the capacity to mount an inﬂammatory response,
can lead to morbidity and mortality in HIV patients.
Case description: A 38 y/o presented with fever and weight loss.
HIV test was positive and blood culture grew Crytococcus Neofor-
mans. CD4 was 45 cells/ml and viral load (VL) 800,000 copies/ml.
Chest CT revealed hilar lymphadenopathy and RLL lesion. Few
weeks into treatment with Amphotericin B and subsequently Flu-
conazole, combination antiretroviral therapy (CART) was added
to PCP and MAC prophylaxis. After 4 weeks, he presented with
fever and cervical lymphadenopathy. CD4 was 322, VL 80,000.
Bronchial washing showed Cryptococcus and MAC. Amphotericin
B, Rifabutin, Ethambutol and Azithromycin were started. One
month later fever and lymphadenopathy continued. Biopsy of
a node showed necrotizing granuloma due to MAC. IRIS with
Disseminated MAC was diagnosed and considering progressive
